Generic Anturol Availability

Anturol is a brand name of oxybutynin, approved by the FDA in the following formulation(s):

ANTUROL (oxybutynin - gel, metered; transdermal)

  • Manufacturer: WATSON LABS INC
    Approval date: December 7, 2011
    Strength(s): 3% [RLD]

Has a generic version of Anturol been approved?

No. There is currently no therapeutically equivalent version of Anturol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anturol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compositions and methods for transdermal oxybutynin therapy
    Patent 7,029,694
    Issued: April 18, 2006
    Inventor(s): Ebert; Charles D. & Sanders; Steven W.
    Assignee(s): Watson Laboratories, Inc.
    The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
    Patent expiration dates:
    • April 26, 2020
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
      ✓ 
      Drug product
  • Compositions and methods for transdermal oxybutynin therapy
    Patent 7,179,483
    Issued: February 20, 2007
    Inventor(s): Ebert; Charles D. & Sanders; Steven W.
    Assignee(s): Watson Pharmaceuticals, Inc.
    The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
    Patent expiration dates:
    • April 26, 2020
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
  • Formulations for transdermal or transmucosal application
    Patent 7,198,801
    Issued: April 3, 2007
    Inventor(s): Carrara; Dario Norberto R. & Grenier; Arnaud & Besse; Celine & Simes; Stephen M. & Lehman; Leah M.
    Assignee(s): Antares Pharma IPL AG
    The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
    Patent expiration dates:
    • June 25, 2022
      ✓ 
      Drug product
  • Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
    Patent 8,241,662
    Issued: August 14, 2012
    Inventor(s): Ebert; Charles D. & Sanders; Steven W.
    Assignee(s): Watson Laboratories, Inc.
    The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
    Patent expiration dates:
    • April 26, 2020
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 7, 2014 - NEW PRODUCT

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web1)